DIGITAL TWINS
Medical Avatars for Precision Medicine
Mavatar’s Medical Avatars transform molecular data into patient-specific digital twins—enabling in silico therapy simulations, smarter clinical decisions, and faster drug development.
Personalized Models for Smarter Decisions
At the core of Mavatar’s precision medicine approach is our Digital Twin technology, also known as Medical Avatars. These advanced, virtual models replicate the complex molecular and cellular features of both patients and diseases—providing a new layer of biological insight to support treatment selection and therapeutic innovation.
Powered by DINA
Built on our proprietary Deep Integrated Network Analysis (DINA) framework, Medical Avatars are created using vast amounts of single-cell RNA sequencing (scRNA-seq) and transcriptomic data. This allows our platform to simulate biological processes and treatment effects at a highly detailed level—purely through data, without the need for real-time tissue sampling.
Treatment Support for Clinicians
Medical Avatars are used to match individual patients to disease subgroups based on their biomarker profile, collected via a standard blood test. Once matched, the platform simulates how different therapies might interact with that patient’s unique molecular signature—helping clinicians make more personalized and informed treatment decisions.
Each avatar is pre-computed using data from hundreds of real cases, enabling rapid, scalable analysis. Physicians receive a ranked list of potential treatment options, based on how closely they align with the patient’s disease profile.
This capability is being integrated into Mavatar Precision, our upcoming clinical decision support platform, launching in 2026.
Additional disease models are in development and will continue to expand over time.
The first focus areas include:
How It Works
Blood-Based Biomarker Test
Avatar Matching
In Silico Testing
Accelerating Drug Development
All Cells. All Genes. All Diseases.
Cross-Disease, Tissue-Specific Discovery
Unbiased Insight Generation
Accelerating Drug Development
Medical Avatars are not only useful in clinical decision support—they can also offer significant value to pharmaceutical R&D teams. By creating disease- and patient-specific digital twins, Mavatar helps:
- Identify high-potential biomarkers and therapeutic targets
- Predict drug efficacy through in silico modeling
- Support drug repurposing opportunities
- Improve trial design and patient subgroup selection
This technology helps reduce early development risks, enhance trial precision, and may improve timelines for bringing new therapies to market.
Supporting Clinical Trials with AI-Powered Biomarkers
Mavatar also offers AI-based biomarker discovery—integrating transcriptomic and single-cell data to identify indicators predictive of therapeutic response. This allows pharma teams to:
- Refine inclusion criteria
- Define stronger endpoints
- Select better-matched patient cohorts
This approach helps streamline trials, reduce costs, and improve outcome predictability across development stages.